key: cord-0965929-3urwfnge
authors: El Sissy, Carine; Saldman, Antonin; Zanetta, Gilbert; Martins, Paula Vieira; Poulain, Coralie; Cauchois, Raphaël; Kaplanski, Gilles; Venetz, Jean-Pierre; Bobot, Mickaël; Dobosziewicz, Hélène; Daniel, Laurent; Koubi, Marie; Sadallah, Salima; Rotman, Samuel; Mousson, Christiane; Pascual, Manuel; Frémeaux-Bacchi, Véronique; Fakhouri, Fadi
title: COVID-19 as a potential trigger of complement-mediated atypical HUS.
date: 2021-09-07
journal: Blood
DOI: 10.1182/blood.2021012752
sha: 97ebe1095eb8ff85665f7df67549d6d156baff47
doc_id: 965929
cord_uid: 3urwfnge

nan

Endothelial cell (EC) injury has emerged as a hallmark of infection due to acute respiratory coronavirus 2 (SARS-Cov2) 1-3 . Complement activation or dysregulation is another notable feature of COVID-19 4, 5 , and elevated plasma levels of sC5b-9, a marker of activation of the complement terminal pathway, have been reported in up to 2/3 of COVID-19 patients 6 , and correlate with disease severity 4,6 .

Complement dysregulation is also a well-established pathogenic mechanism of a rare form of renal thrombotic microangiopathy (TMA), the atypical haemolytic uremic syndrome (aHUS), triggered by complement-induced EC damage 7 .

To date, renal TMA has been very rarely documented in the COVID-19 setting 8, 9 . We report on five patients with COVID-19-associated renal TMA, among whom four tested patients carried complement genetic susceptibility factors for aHUS.

Patients with COVID-19-associated renal TMA were identified using the databases of the French HUS Registry and the Complement reference Centre in Lausanne (Switzerland).

COVID-19 infection was diagnosed in all cases, based on a positive polymerase-chain reaction (PCR) test for SARS-CoV-2 in oropharyngeal swab samples. Renal TMA was defined by at least three of the following criteria: a) thrombocytopenia (platelet count < 150 G/L), b) mechanical hemolytical anaemia (Hb < 10 g/dL, lactate dehydrogenase serum level > upper limit of normal (ULN), undetectable haptoglobin, presence of schistocytes on blood smear), c) acute kidney injury (serum creatinine and/or proteinuria/creatininuria > ULN for age or an increase > 15% compared to baseline) and d) features of TMA in kidney biopsy.

Measurement of plasma C3, C4, CH50, Factor H (FH) and I (FI), sC5b-9 and CD46 expression on granulocytes and tests for anti-FH antibodies were performed as previously described 10 . Screening for variants and complex rearrangements in complement factor H (CFH), complement factor I (CFI), membrane-cofactor protein (MCP), C3 and Factor B genes was performed using next-generation sequencing and multiplex ligation-dependent probe amplification, as previously described 10 . All patients gave informed consent for genetic testing.

Five adult patients with COVID-19-associated renal TMA were identified in five French and Swiss nephrology, renal transplantation and internal medicine units (Table 1 and Supplemental Figure S1 (Table 2) showed increased plasma C3 and C4 levels in all patients (probably as part of the inflammatory response) and mildly increased sC5b-9 plasma level in one patient. FH and FI plasma levels were decreased in one patient. Anti-FH antibodies were detected in two patients. In three out the four patients for whom DNA samples were available, a pathogenic rare variant was detected: one CFH variant which is known to be associated to a decreased plasma FH levels in vivo, one CFI variant associated to a decreased FI synthesis documented in vitro 11 , and one C3 variant associated to an impaired C3 regulation 12 . An additional patient carried, in homozygosity, the haplotype H3 in the CFH gene (tgtgt), an established risk factor for aHUS 7 .

Two patients underwent plasma exchanges with fresh frozen plasma, while three were treated with eculizumab. Patient 4 received two infusions of rituximab for anti-FH antibodies.

At the last known follow-up (1-6 months), two patients remained dialysis-dependent, two renal transplant recipients regained their baseline renal function and a third one had a decreased function of the renal transplant.

Data on COVID-19-associated TMA are scarce 9,13,14 (Supplemental Table S1 ). We here report the first series of renal TMA in COVID-19 patients, which includes extensive complement work-up. The first remarkable finding is the sharp contrast between mild respiratory symptoms but severe renal (and in three patients extra-renal) TMA. Therefore, COVID-19-related morbidity was mainly due to TMA rather than to the pulmonary involvement. Three of the patients in the present series and two from previously published cases are renal transplant recipients. Underlying kidney graft (vascular) damage and tacrolimus/everolimus use and very high trough levels (particularly in patient 2), may have contributed to trigger TMA in the renal graft.

The second remarkable finding is the detection in three tested patients of complement gene variants associated to an altered regulation of the complement alternative pathway, and thus to an increased risk of complement-mediated EC injury. An additional tested patient had the at-risk haplotype (H3) in the CFH gene, which predisposes to aHUS. Interestingly, the only previously reported patient with COVID-19-associated renal TMA and tested for complement gene variants, was found to carry a pathogenic rare variant in the C3 gene and an at-risk haplotype in the MCP gene 9 . Thus, to date, all five reported patients with COVID-19associated renal TMA, who underwent genetic testing, carry a constitutional complement dysregulation. These findings require confirmation in larger series. Noteworthy, two patients were positive for anti-FH antibodies, but the pathogenic relevance of these autoantibodies is unclear, and their presence may reflect the stimulation of the immune system due to COVID-19, rather than a causal role in the TMA.

The discussion of the role of systemic complement activation has been one of the central issues in the management of COVID-19 patients 6, [15] [16] [17] [18] [19] . Limited preliminary reports suggested a potential benefit of C5 blockade in severe forms of COVID-19 6, 15 , but two prospective studies did not show any clear benefit of C5 or C5a blockade in this setting 20, 21 .

However, the patients presented here had mild pulmonary COVID-19 manifestations and absent or moderate markers of systemic complement activation. These findings suggest that TMA in our patients resulted predominantly from intra-renal complement activation and ensuing EC damage, associated to a genetic dysregulation of the complement alternative pathway in at least four patients -i.e. a clinical and genetic pattern of renal TMA similar to the one reported in complement-mediated aHUS. These similarities suggest that HUS is not a unique manifestation of COVID19, but rather that COVID-19 is a newly identified potential infectious trigger for aHUS, in accordance with previous data on complement-mediated aHUS precipitated by viral infections, mostly influenza strains 22 . The awareness of a potential association of COVID-19 with complement-mediated aHUS, may help improve patients' management. The use of anti-complement therapies should be considered in this form of HUS associated to COVID-19, to potentially limit kidney damage. However, the limited number of patients in the present series preclude any firm conclusions, and additional data are required.

In conclusion, COVID-19 is a potential newly identified trigger for complementmediated aHUS. The identification of such association has important clinical implications and additional data are required.

CES, VF-B and FF reviewed the data and drafted the manuscript. CES, PVM, AS, SS and VF-B performed the complement work-up. SR and LD analysed the kidney biopsies. All the authors were involved in the management of the patients. All authors read, commented and revised the manuscript before approval.

We are grateful to Dr Carole Gengler (Service of Clinical Pathology, Lausanne University Hospital, Switzerland) for her assistance in reviewing the kidney pathological data.

GK received fees from SOBI and Roche for invited lectures.

VF-B has received fees from Alexion Pharmaceuticals, Roche, BioCryps and Apellis for invited lectures and/or board membership and is the recipient of a research grant from Alexion Pharmaceuticals.

FF has received consultancy and/or speaker honoraria from Roche, Alexion, Apellis, Achillion, Novartis and Alnylam. 

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19

Endothelial cell infection and endotheliitis in COVID-19

Circulating Endothelial Cells as a Marker of Endothelial Injury in Severe COVID -19

Complement Overactivation and Consumption Predicts In-Hospital Mortality in SARS-CoV-2 Infection

Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition

Complement C5 inhibition in patients with COVID-19 -a promising target

Haemolytic uraemic syndrome

Thrombotic microangiopathy in a patient with COVID-19

Kidney Thrombotic MicroAngiopathy after COVID-19 associated with C3 gene mutation

Complement Gene Variants and Shiga Toxin-Producing Escherichia coli-Associated Hemolytic Uremic Syndrome: Retrospective Genetic and Clinical Study

Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome

Rare variants in CFI, C3 and C9 are associated with high risk of advanced age-related macular degeneration

Thrombotic Microangiopathy in a Kidney Transplant Patient With COVID-19

COVID-19 Manifesting as Renal Allograft Dysfunction, Acute Pancreatitis, and Thrombotic Microangiopathy: A Case Report

Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: A proof-of-concept study

Severe COVID-19 infection and thrombotic microangiopathy: success does not come easily

The case of complement activation in COVID-19 multiorgan impact

Genetic justification of severe COVID-19 using a rigorous algorithm

Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis

Complement cascade in severe forms of COVID-19: Recent advances in therapy

Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, openlabel, phase 2 randomised controlled trial

Influenza-associated thrombotic microangiopathies